Core Biotherapeutics

Rick Orr, JD

Chairman & Co-Founder

Rick brings 30 years of biotechnology leadership spanning company formation, clinical development, corporate finance, and strategic acquisitions. He previously served as CEO of Exalys Therapeutics and Adynxx, and as COO of Corthera and Calixa, leading their respective acquisitions by Novartis for $620 million and Cubist Pharmaceuticals for $410 million. As a founder and General Counsel of Cerexa, he helped guide the company through its $480 million acquisition by Forest Laboratories and subsequently supported the clinical development of Teflaro®. Earlier, he played a key role in Peninsula Pharmaceuticals’ $245 million acquisition by Johnson & Johnson. Rick began his legal career at Cooley LLP and holds a JD from the University of San Francisco School of Law.

Scroll to Top